Friday 22 August 2014

Bio-high-tech treatment for Ebola may have saved two US citizens

Science Focus

original post »
The Ebola virus consists of small but lethal filament of RNA containing only seven genes.

CNN reported Monday that the two US citizens who were flown back to the states after contracting the Ebola virus were given an extremely experimental treatment, one that's still undergoing animal testing. While the treatment involves antibodies, it's not a vaccine, and it can work effectively even after an infection has started. The process that produced it is a testament to the impressive capabilities developed in the field of biotechnology.

The Ebola virus, known for its horrific symptoms and high fatality rate, currently has no established treatment. The health care workers who are fighting the disease—and are thus at high risk for becoming infected themselves—can do little more than put themselves in isolation and try to compensate for the damage the virus causes. That situation was apparently the case for two Americans who contracted the virus while working in Liberia.

In this case, however, both people were apparently given an experimental treatment developed in part by a company called Mapp Biopharmaceutical. Complicating matters, Mapp licenses its developments to a company called LeafBio for production and distribution. But LeafBio has also licensed an Ebola treatment from a second company, called Defyrus, and it plans on combining the two. It's unclear whether the Americans received the original or combined therapy. In either case, both therapies were based on the same developmental process outlined below.

Read 9 remaining paragraphs | Comments

 
#science 
 » see original post http://feeds.arstechnica.com/~r/arstechnica/science/~3/itMy7VJ31EA/
See Zazzle gifts tagged with 'science'

No comments:

Post a Comment